ῌ,**/ The Japanese Society for AIDS Research

The Journal of AIDS Research HIV Alert for Outbreak of Drug Resistance HIV-+ in Newly Infected Population
Wataru SUGIURA


National Institute of Infectious Diseases :   HIV-+   1 : ++1῍+,* ,**/

02,p/<

+32/  zidovudine !"+# HIVῌAIDS $%&'()*+, ,* -./ 01$2$34'!" HIV-+ ,6 HIV-+ / 6W;VK-5.02607689%,-:V5(/,-:;)< N + ;<  +1 &= >?@ABCDEFGH 1 I

X\rA,de". !>?@ABCDEFGH - I  J'(KLMNOH 1 I  PQ +1 IR"!"

HIV-+ V/< &=\]^_@K

2OP$f/

X2Z.,῍,+#< 0NXqQ'(R/6 nOl de".\))e* (/< S#!".TUPVWXYZ/2 J$6!*%[ ,- IHIV STUVCpkV5(/02,-/< qrW2'(6 XH  M`a OHVW.V?abJ'(3cde"(f +ghi$&'j%[\;qrW2'( -YZ [  \I ¡(k02l(!"/< )*+m,-'( 0"n]# HIV-+ |¢X[/£^_V¤¥,-W.$$o*"(p./6061k qrq/|C)*Z¦§'(.0r.s HIVῌAIDS Xt2u/.Z3k'(2\[*"/<p.45672[;<*V5(.02*"/<0;

89V02$:;6 HIV-+ 2,HIV-+ STU¨*rkq`

1,©a'(*"(/9Y\-/< J"6;.Vv<X3p =".$%&/w>

W f(\x?6 y.s)* HIV-+ -u/z"X@"

FGH,ª\«02,-/< 0"6N¬ui!{rr-/;,-/< +,6 AB,6STU>?@ABCDE

b,­>?@ABCDEFGH6HIV-+ /.V|C}D!"(/ 0"6+* ®k$"*"(p.2V5(f HIV-+0;V~bEJ'(FvG-/2Zc>?@ABCDEFGH[*"/< -/6 bd¯'rr-/02Xe°'(/,-:;< 0HIV )HIJ,6Vk

/|C6UaNVW$~

"-'(!>?@ABCDEFGH2KLMde"(/0f(\upCpV

N OH-u/

J2V5(/02X[/2 +K6 HIV (f±g"he5(/ ²³!>?@ABCD:;'.)**Z*"(.LM,-/2\[/nopA :   ¸,*2῍**++ qrs¹º» .῍1῍+#Fax : *.,῍/0+῍1..0,**/  0 ¼ ,* ·tSTUr(6 5STUn;«;,-/< 0"* , ?ab
6>?@ABCDEFGHi/2 R"j´k  b,$lU# .Z,-:;<N¬'. n2µW(de"(/ ¶m¥5¶m¥2· X++1

 /1 #

W Sugiura : Alert for Outbreak of Drug Resistance HIV-+ in Newly Infected Population ,Simon  Little   ῍-&' ()*+,-./0123456789:;

 <56& ῍,,  !"#$ %ῌ +CDE

=>?@AFGHIJKB' )*+,-./012

LMprevalence

Author and Groupcountryyear

testN

refTotal

NRTI NNRTI

PI

Novak RM+

Terry Berin Community Programs for cli-US+333ῌ,**+Genotyping

nN.3+

++40ῌ

142ῌ

-4*ῌ

*41ῌ

+*.

nical Research on AIDS_*/2 study teamLittle SJ,

Richmann DD

Genotyping

nN,+-24*ῌ

24/ῌ+41ῌ

*43ῌ

Phenotyping
Genotyping

nN,0.
nN22-4.ῌ
,,41ῌ

,4-ῌ+/43ῌ

+43ῌ
14-ῌ

*4.ῌ
+*4,ῌ

Phenotyping

nN++.

+,4.ῌ

24/ῌ

14+ῌ

24*ῌ

+33/ῌ,**+

Genotyping
Phenotyping

nN10
nN0*+-4,ῌ
+*4*ῌ

++42ῌ
24-ῌ

,40ῌ
-4*ῌ

+4-ῌ
+41ῌ

+333ῌ,**+

Genotyping
Phenotyping

nN12
nN1.

+341ῌ
+*42ῌ

+.4/ῌ
,41ῌ

040ῌ
24+ῌ

/4+ῌ
/4.ῌ

+33/ῌ+332
USA+333ῌ,***Simon V & Markowitz M-USA3.

Wegner S
US military

USA+331ῌ+332

Genotyping
Phenotyping

nN3/
nN3+,,4+ῌ
,341ῌ

.4*ῌ
24*ῌ

+/4*ῌ
,04*ῌ

+*4*ῌ
+4*ῌ

0/

Weinstock HS

USA+331ῌ,**+Genotyping

nN+*2,24-ῌ

04.ῌ

+41ῌ

+43ῌ+,

USA+333

Genotyping

nN22+24*ῌ

+.4*ῌ

/4*ῌ

,4*ῌ

+++,4/ῌ

14/ῌ

-42ῌ

+.

-42ῌ

,0

Hanna GJ
D’Aqila RT

1

Boden D
Markowiz M

USA+333

Genotyping

nN2*+04-ῌ2

Alexander CS

Canada+331ῌ+332

Genotyping

nN.1304-ῌ

Alexander CS

CanadaVancouver+330ῌ+332

Genotyping

nN/1+34,ῌ+.4*ῌ

14*ῌ

+43ῌ

-+331ῌ,***,**+ῌ,**-Genotyping
Genotyping

nN+,1nN/-+-4*ῌ
.4*ῌ

++4*ῌ
*4*ῌ

,4.ῌ
+43ῌ

/4/ῌ
+43ῌ+/Montreal
Canada+331ῌ+333

Genotyping
Genotyping

nN/0nN,+**NR*NR+,4*ῌ
,.4*ῌ

+23+*Routy JP

Canada-4.ῌ

,,4*ῌ
,.4*ῌ

++

Salomon H
Quebec Primary Infection Study+,

UK collaborative Group on Monitoring
the transmission of HIV Drug Resistance

UK+33.ῌ,***Genotyping

nN03+.4/ῌ++40ῌ

.4-ῌ

+4.ῌ

/+-Descamps D
ANRS antiretroviral Resistance Study

France+332

Genotyping

nN-3+-41ῌ
O/+4+ῌP-4-ῌ

*42ῌ

+43ῌ
O.34,ῌP2+.

Chaix MLFrance+333ῌ,***Genotyping

nN,.3+*4*ῌ

24*ῌ

.4*ῌ

04*ῌ1+/Duwe

Germany+330ῌ+333

Genotyping

/4*ῌ

+0+0

Romano L

Italy+330ῌ,***Genotyping

nN++0+,43ῌ+,43ῌ

*4*ῌ

*43ῌ

+-+1

Martinz-Picado

Spain,**.

Genotyping

nN+2,-42ῌ

,4,ῌ

+4+ῌ

*4/ῌ

,*+2

Maljkovic I

Sweden+332ῌ,**+Genotyping

nN+**

34*ῌ

14*ῌ

/4*ῌ

+4*ῌ

,++3

Jorgensen LB

Denmark,***

Genotyping

NR,4*ῌ

*4*ῌ

+3,*

Ammoranond P

Australia+33,ῌ,**+Genotyping

NR34*ῌ

*4*ῌ

+1* NR : Not reported** : IVDU data++2 O /2 PNR34*ῌThe Journal of AIDS Research Vol. 1 

  HIV-+ !"#$% &'&' ()* +,- ./ + 01

+·No. ,,**/

HRª HIV-+ GH+6

'º+,GZ_F!GD»[῏῍

2034 5"#$%6+7 *+  Mitsuya H, Weinhold KJ, Furman PA, St. Clair MH,- 89:;<=>?@/Lehrman SN, Gallo RC, Bolognesi D, Barry DW,

A6BCDEF+Broder S : -῎-Azido--῎-deoxythymidine (BW A/*3U) :IDJ+ K an antiviral agent that inhibits the infectivity and- L6MGNO HIV-+cytopathic e#ect of human T-lymphotropic virus type

PQR#ST%G N- 6BIII/lymphadenopathy-associated virus in vitro. ProcE21U3Natl Acad Sci U S A 2, : 1*30ῌ1+**, +32/.

ῌ῎,G H
,0MV, Mo T, Piaseczny MA, Montaner JS, Harrigan PR :

#$

HIV protease and reverse transcriptase variation and  H6W- XYGHZ[\] ^%therapy outcome in antiretroviral-naive individuals fromHIV-+6,  Alexander CS, Dong W, Chan K, Jahnke N, O’Shaughnessy

GV!"

6&'_ `ab cd- e f(a large North American cohort. Aids +/ : 0*+ῌ0*1, ,**+.

g)*3+ aD+ h i+"#-  Alexander CS, Dong W, Schechter MT, O’Shaughnessy$%L6MGjkldXYῌf(MV, Strathdee SA, Mo T, Montaner JS, Harrigan PR :g)Gmn o,Prevalence of primary HIV drug resistance amongp-G NewYork Times ./q3+0r0s12\ tseroconverters during an explosive outbreak of HIV in-"#$%3uvwQxQ9y4z{GHk- fection among injecting drug users. Aids +- : 32+ῌ32/,HIV-+ j00l5G6| }7~Oq+333.

8 9:q3+  H./+.  Little SJ, Holte S, Routy JP, Daar ES, Markowitz M,;<  +=1

Collier AC, Koup RA, Mellors JW, Connick E, Conway

H- 6M+* 6G + 6G"#$%

B, Kilby M, Wang L, Whitcomb JM, Hellmann NS,

q3> ld-  H?1

Richman DD : Antiretroviral-drug resistance among pa-

1@3q!3 N-  WAG"tients recently infected with HIV. N Engl J Med -.1 :#$% cdBE- 0C+G

-2/ῌ-3., ,**,.

DE B"#$%k+F!Gq3/  UK Collaborative Group on Monitoring the Transmis-

+WAC1G(- s12\D6

sion of HIV Drug Resistance : Analysis of prevalence ofM .G* Hq3 HIV-+ drug reistance in primary infections in the United,,

GNOL6M
 ,**- ,G , 0 HIV-+ G0

$Q

GH

Kingdom. BMJ -,, : +*21ῌ+*22, ,**+.

\30  Wegner SA, Brodine SK, Mascola JR, Tasker SA,+  ? T¡Q¢#£?ῌI( T¡Q

Sha#er RA, Starkey MJ, Barile A, Martin GJ, Aronson

$QGH .῍-  I¤¥? T¡Q

N, Emmons WW, Stephan K, Bloor S, Vingerhoets J,

$QGH +1῍ q3+,-

Hertogs K, Larder B : Prevalence of genotypic andGDIDJ,!3

phenotypic resistance to anti-retroviral drugs in a cohort

- 3KLGN1 HIV-+ GH6AMof therapy-naive HIV-+ infected US military personnel.

 HG , 0Gm{¦E§ ,0NO +0 ,H¨PQ©¢#£Rªc«+ 0L6MGNO HIV-+PQ¬­#ST%I®q3+

Aids +. : +**3ῌ+*+/, ,***.
1  Chaix ML, Descamps D, Harzic M, Schneider V,Deveau C, Tamalet C, Pellegrin I, Izopet J, Ru#ault A,

 HIV-+ S?G¯Masquelier B, Meyer L, Rouzioux C, Brun-Vezinet F,

T °±²9³ - ³ U´ µ-  Costagliola D : Stable prevalence of genotypic drug re-VW* ¶µ- M·0E 6| ¸XC2sistance mutations but increase in non-B virus among,!3 patients with primary HIV-+ infection in France. Aids +1 :

\GH- KL L6

MGNO HIV-+jY¹G )D-,0-/ῌ,0.-, ,**-.

++3¼ /3 

W Sugiura : Alert for Outbreak of Drug Resistance HIV-+ in Newly Infected Population

2 ῍ Descamps D, Calvez V, Izopet J, Bu#et-Janvresse C,P, Baril JG, Remis RS, Sekaly RP, Wainberg. MA :Schmuck A, Colson P, Ru#ault A, Maillard A,Factors associated with a decrease in the prevalence ofMasquelier B, Cottalorda J, Harzic M, Brun-Vezinet F,drug resistance in newly HIV-+ infected individuals in

Costagliola D : Prevalence of resistance mutations inMontreal. Aids +2 : ,-*/ῌ,-+,, ,**..

antiretroviral-naive chronically HIV-infected patients in+0῍ Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B,+332 : a French nationwide study. Aids +/ : +111ῌ+12,,

Walter H, Pauli G, Kucherer C : Frequency of genotypic,**+.

and phenotypic drug-resistant HIV-+ among therapy-

3 ῍ Simon V, Vanderhoeven J, Hurley A, Ramratnam B,

naive patients of the German Seroconverter Study. J

Louie M, Dawson K, Parkin N, Boden D, Markowitz M :Acquir Immune Deﬁc Syndr ,0 : ,00ῌ,1-, ,**+.

Evolving patterns of HIV-+ resistance to antiretroviral+1῍ Ammaranond P, Cunningham P, Oelrichs R, Suzuki K,

agents in newly infected individuals. Aids +0 : +/++ῌ

Harris C, Leas L, Grulich A, Cooper DA, Kelleher AD :+/+3, ,**,.

No increase in protease resistance and a decrease in+*῍ Novak RM, Chen L, MacArthur RD, Baxter JD,

reverse transcriptase resistance mutations in primary

Huppler Hullsiek K, Peng G, Xiang Y, Henely C,HIV-+ infection : +33,ῌ,**+. Aids +1 : ,0.ῌ,01, ,**-.

Schmetter B, Uy J, van den Berg-Wolf M, Kozal M :+2῍ Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau

Prevalence of antiretroviral drug resistance mutations inD, Cote P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C,

chronically HIV-infected, treatment-naive patients : im-

Sekaly RP, Conway B, Mayers D, Routy JP : Prevalence

plications for routine resistance screening before initia-of HIV-+ resistant to antiretroviral drugs in 2+ individu-

tion of antiretroviral therapy. Clin Infect Dis .* : .02ῌals newly infected by sexual contact or injecting drug use.

1.. Epub ,**/ Jan +*, ,**/.

Investigators of the Quebec Primary Infection Study.

++῍ Hanna GJ, Balaguera HU, Freedberg KA, Werner BG,

Aids +. : F+1ῌ,-, ,***.

Steger Craven KA, Craven DE, D’Aquila RT : Drug-+3῍ Jorgensen LB, Christensen MB, Gerstoft J, Mathiesen

selected resistance mutations and non-B subtypes in anti-LR, Obel N, Pedersen C, Nielsen H, Nielsen C : Preva-

retroviral-naive adults with established human im-lence of drug resistance mutations and non-B subtypes inmunodeﬁciency virus infection. J Infect Dis +22 : 320ῌ

newly diagnosed HIV-+ patients in Denmark. Scand J

33+. Epub ,**- Sep +*, ,**-.

Infect Dis -/ : 2**ῌ2*1, ,**-.

+,῍ Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-,*῍ Martine-Picado J, Guiterrez C, deMendoza C, Erkicia I,

Lerma JG, Douglas JM, Jr., LaLota M, Dickinson G,Domingo P, Camino X, Galindo MJ, Blaonco JL, Leal

Schwarcz S, Torian L, Wendell D, Paul S, Goza GA,M, Masabeu A, Guelar A, Baldovi JF, Pedereia JD,Ruiz J, Boyett B, Kaplan JE : The epidemiology of anti-Gatell JM, Moreno S, Clotet B, Soriano V, Ruiz J :retroviral drug resistance among drug-naive HIV-+-

Presented at the +.th international HIV drug resistanceinfected persons in +* US cities. J Infect Dis +23 : ,+1.ῌ

workshop, Quebec City, Canada, June 1ῌ++, ,**/. ,**/.

,+2*. Epub ,**. May ,+, ,**..
+-῍ Romano L, Venturi G, Ferruzzi R, Riccio ML, Corsi P,,+῍ Maljkovic I, Wilbe K, Solver E, Alaeus A, Leitner T :Limited transmission of drug-resistant HIV type + in +**Leoncini F, Vinattieri A, Incandela L, Valensin PE,Swedish newly detected and drug-naive patients infectedZazzi M : Detection of genotypically drug-resistant HIV-with subtypes A, B, C, D, G, U, and CRF*+_AE. AIDS+ variants and non-B subtypes in recently infected antiretroviral-naive adults in Italy. Aids +. : ,,*.ῌ,,*0,,***.
+.῍ Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E,Res Hum Retroviruses +3 : 323ῌ331, ,**-.
,,῍ Volberding PA : The New York case : lessons being
learned. Ann Intern Med +., : 200ῌ202. Epub ,**/ Apr,+, ,**/.

Tsay J, Ip J, Farthing C, Limoli K, Parkin N, Markowitz,-῍ Ibe S, Hotta N, Takeo U, Tawada Y, Mamiya N,

M : HIV-+ drug resistance in newly infected individuals.

Yamanaka K, Utsumi M, Kaneda T : Prevalence of drug-Jama ,2, : ++-/ῌ++.+, +333.

resistant human immunodeﬁciency virus type + in+/῍ Routy JP, Machouf N, Edwardes MD, Brenner BG,Thomas R, Trottier B, Rouleau D, Tremblay CL, Cote+,* ῌ 0* ῍

therapy-naive patients and usefulness of genotype testing.
Microbiol Immunol .1 : .33ῌ/*/, ,**-.